Publications by authors named "Saya Moriyama"

Claim this Profile
O
Optimizing the breadth of SARS-CoV-2-neutralizing antibodies in vivo and in silico.
Daisuke Kuroda, Saya Moriyama, Hiroaki Sasaki, Yoshimasa Takahashi

Hum Vaccin Immunother· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antibody durability is influenced by interleukin-2 production by undifferentiated memory T helper cells and extensive B cell clonal expansion.
Masanori Isogawa, Masahiro Shinoda, Ryutaro Kotaki, Kazutaka Terahara, Taishi Onodera, Saya Moriyama

Cell Rep· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Calboxyvinyl polymer adjuvant enhances respiratory iga responses through mucosal and systemic administration.
Eita Sasaki, Hideki Asanuma, Haruka Momose, Jun-Ichi Maeyama, Saya Moriyama

NPJ Vaccines· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Atypical memory B cells from natural malaria infection produced broadly neutralizing antibodies against Plasmodium vivax variants.
Piyawan Kochayoo, Saya Moriyama, Ryutaro Kotaki, Pongsakorn Thawornpan, Chayapat Malee

PLoS Pathog· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Repeated Omicron exposures redirect SARS-CoV-2-specific memory B cell evolution toward the latest variants.
Ryutaro Kotaki, Saya Moriyama, Shintaro Oishi, Taishi Onodera, Yu Adachi

Sci Transl Med· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mpox Neutralizing Antibody Response to LC16m8 Vaccine in Healthy Adults.
Eriko Morino, Sohtaro Mine, Noriko Tomita, Yukari Uemura, Yosuke Shimizu, Saya Moriyama

NEJM Evid· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Post-fusion influenza vaccine adjuvanted with SA-2 confers heterologous protection via Th1-polarized, non-neutralizing antibody responses.
Ayae Nishiyama, Yu Adachi, Keisuke Tonouchi, Saya Moriyama, Lin Sun

Vaccine· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structural delineation and computational design of SARS-CoV-2-neutralizing antibodies against Omicron subvariants.
Saya Moriyama, Yuki Anraku, Shunta Taminishi, Yu Adachi, Daisuke Kuroda

Nat Commun· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Potent neutralizing broad-spectrum antibody against SARS-CoV-2 generated from dual-antigen-specific B cells from convalescents.
Masaru Takeshita, Hidehiro Fukuyama, Katsuhiko Kamada, Takehisa Matsumoto, Chieko Makino-Okamura, Saya Moriyama

iScience· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CD62L expression marks SARS-CoV-2 memory B cell subset with preference for neutralizing epitopes.
Taishi Onodera, Nicolas Sax, Takashi Sato, Yu Adachi, Ryutaro Kotaki, Saya Moriyama

Sci Adv· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Saturation time of exposure interval for cross-neutralization response to SARS-CoV-2: Implications for vaccine dose interval.
Sho Miyamoto, Yudai Kuroda, Takayuki Kanno, Akira Ueno, Nozomi Shiwa-Sudo, Saya Moriyama

iScience· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Heterologous SARS-CoV-2 spike protein booster elicits durable and broad antibody responses against the receptor-binding domain.
Tomohiro Takano, Takashi Sato, Ryutaro Kotaki, Saya Moriyama, Shuetsu Fukushi

Nat Commun· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Non-Omicron breakthrough infection with higher viral load and longer vaccination-infection interval improves SARS-CoV-2 BA.4/5 neutralization.
Sho Miyamoto, Takeshi Arashiro, Akira Ueno, Takayuki Kanno, Shinji Saito, Saya Moriyama

iScience· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multimodal single-cell analyses of peripheral blood mononuclear cells of COVID-19 patients in Japan.
Yukie Kashima, Taketoshi Mizutani, Kaori Nakayama-Hosoya, Saya Moriyama, Takayuki Matsumura

Sci Rep· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Specific COVID-19 risk behaviors and the preventive effect of personal protective equipment among healthcare workers in Japan.
Reiko Shimbashi, Teiichiro Shiino, Akira Ainai, Saya Moriyama, Satoru Arai

Glob Health Med· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Neutralizing antibodies against SARS-CoV-2].
Saya Moriyama

Uirusu· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Humoral immunity for durable control of SARS-CoV-2 and its variants.
Ryutaro Kotaki, Saya Moriyama, Yoshimasa Takahashi

Inflamm Regen· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Potent SARS-CoV-2 neutralizing antibodies with therapeutic effects in two animal models.
Masaru Takeshita, Hidehiro Fukuyama, Katsuhiko Kamada, Takehisa Matsumoto, Chieko Makino-Okamura, Saya Moriyama

iScience· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of Fcγ receptor-dependent binding of influenza hemagglutinin vaccine-induced antibodies in a non-human primate model.
Yuji Masuta, Shokichi Takahama, Takuto Nogimori, Saya Moriyama, Yoshimasa Takahashi

iScience· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Different efficacies of neutralizing antibodies and antiviral drugs on SARS-CoV-2 Omicron subvariants, BA.1 and BA.2.
Hirofumi Ohashi, Takayuki Hishiki, Daisuke Akazawa, Kwang Su Kim, Joohyeon Woo, Saya Moriyama

Antiviral Res· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SARS-CoV-2-specific CD4 T cell longevity correlates with Th17-like phenotype.
Kazutaka Terahara, Takashi Sato, Yu Adachi, Keisuke Tonouchi, Taishi Onodera, Saya Moriyama

iScience· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and immunogenicity of the Pfizer/BioNTech SARS-CoV-2 mRNA third booster vaccine dose against the BA.1 and BA.2 Omicron variants.
Yohei Seki, Yasuo Yoshihara, Kiyoko Nojima, Haruka Momose, Shuetsu Fukushi, Saya Moriyama

Med· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune evasion and chronological decrease in titer of neutralizing antibody against SARS-CoV-2 and its variants of concerns in COVID-19 patients.
Masaru Takeshita, Naoshi Nishina, Saya Moriyama, Yoshimasa Takahashi, Makoto Ishii

Clin Immunol· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Distinct immune cell dynamics correlate with the immunogenicity and reactogenicity of SARS-CoV-2 mRNA vaccine.
Tomohiro Takano, Miwa Morikawa, Yu Adachi, Kiyomi Kabasawa, Nicolas Sax, Saya Moriyama

Cell Rep Med· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Longitudinal Analysis of Neutralizing Potency against SARS-CoV-2 in the Recovered Patients after Treatment with or without Favipiravir.
Kanako Shinada, Takashi Sato, Saya Moriyama, Yu Adachi, Masahiro Shinoda

Viruses· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis